Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
159
resultados
Última actualización
07/05/2025 [07:36:00]
Resultados 75 a 100 de 159
Resumen de: WO2023235863A1
Engineered SARS-CoV-2 variants having a combination of attenuating modifications, and their use as live-attenuated SARS-CoV-2 vaccines, are described. The recombinant genome of the live-attenuated SARS-CoV-2 encodes a modified spike (S) protein with a deletion of the polybasic site (DPRRA); encodes a modified non-structural protein 1 (Nsp1) with K164A and H165A substitutions; and includes a mutation that prevents expression of open reading frames (ORFs) 6, 7a, 7b and 8. The disclosed live-attenuated SARS-CoV-2 retain the capacity to infect and replicate in mammalian cells. Immunogenic compositions that include a live-attenuated SARS-CoV-2 and methods of eliciting an immune response against SARS-CoV-2 in a subject are also described. Further disclosed are a collection of reverse genetics plasmids that include the complement of the recombinant genome of the live-attenuated SARS-CoV-2 and methods of producing a live-attenuated SARS-CoV-2 using the reverse genetics plasmids.
Resumen de: US2025108106A1
This disclosure is directed to a pharmaceutical composition for treating or preventing a disease. The pharmaceutical composition can comprise a polymer-drug nanoaggregate having a polymer and at least one bioactive agent that can comprise STING polypeptide, a nucleic acid encoding said STING polypeptide, a STING inhibitor, a STING activator, a STING agonist, a STING antagonist, a STING modulating molecule, or a combination thereof. The pharmaceutical composition can be a vaccine or an adjuvant for a vaccine. This disclosure is also directed to a method for treating or preventing a disease using the pharmaceutical composition. The disease can include infectious diseases caused by viruses or other pathogens, for example, influenza, rabies, or respiratory illnesses such as severe acute respiratory syndrome (SARS) caused by coronaviruses, such as MERS-CoV, SARS-CoV, and Coronavirus Disease 2019 (COVID-19) caused by the virus SARS-CoV-2 and its variants.
Resumen de: US2025108108A1
A hybrid vaccine composition that prevents infection or reinfection by both influenza and coronaviruses, comprising at least a portion of a Coronavirus spike(S) protein and at least a portion of at least one influenza hemagglutinin (HA) protein. The portion of the coronavirus spike(S) protein is highly conserved among human and animal coronaviruses. The vaccine composition may comprise a Coronavirus protein comprising either: a structural protein, e.g., a Spike protein, a Nucleocapsid protein, or a combination thereof, or a non-structural protein, e.g., NSP2, NSP3, NSP14, or combination thereof; and at least a portion of at least one influenza hemagglutinin (HA) protein.
Resumen de: US2025110112A1
Methods for diagnosing a subject for a COVID-19 infection state include collecting an alveolar air breath sample from a subject; passing the breath sample into contact with a volatile organic compound (VOC) sensor operable to detect a plurality of VOC biomarkers for a COVID-19 infection state; producing a readable sensor output for at least two of the plurality of biomarkers; and diagnosing the COVID-19 infection state of the subject based on the readable sensor output. Systems for detecting and identifying at least one VOC biomarker for a COVID-19 infection state in exhaled breath of a subject include a mouth piece connected to a housing, the mouth piece operable to receive the exhaled breath of the subject; a sensor module disposed in the housing, the sensor module operable to detect the at least one VOC biomarker in the exhaled breath, and further operable to produce a readable sensor output for the at least one VOC biomarker; and a communication module disposed in the housing and in communication with the sensor module, the communication module operable to transmit collected data from the sensor module.
Resumen de: AU2023361023A1
The invention relates to pharmaceutical product comprising a polynucleotide for use in the prevention or treatment of a SARS-CoV-2 virus infection wherein said SARS-CoV-2 virus is not a Wuhan wild-type SARS-CoV-2 virus. The polynucleotide encodes an attenuated human coronavirus or a fragment thereof, wherein the polynucleotide comprises at least 20 one-to-stop codons, wherein a one-to-stop codon is i) a different but synonymous codon compared to the corresponding codon in a natural human coronavirus genome and ii) differs by one nucleotide from a STOP codon.
Resumen de: AU2023341167A1
The present disclosure relates to methods of treating Alzheimer's disease, diseases and/or conditions associated with Covid-19 infection, including long COVID, a post-acute infection syndrome, or symptoms of orthostatic intolerance comprising administration of a therapeutically-effective combination of a COX-2 inhibitor and an antiviral compound.
Resumen de: WO2025067013A1
An anti-SARS-CoV-2 virus protein or mRNA vaccine, a preparation method therefor, and a use thereof. The protein has one or more amino acid residues added, deleted, or replaced in the amino acid sequence as shown in SEQ ID NO: 18. The nucleic acid encodes an S protein mutant. Preclinical animal test data shows that the mRNA vaccine has a good protective effect for the current variants of concern (VOC) of the SARS-CoV-2 virus and has broad clinical application prospects.
Resumen de: WO2025067202A1
Provided herein are methods for treating or preventing a disease caused by veterinary coronavirus in a non-human animal suffering from coronavirus infection, in particular, feline coronavirus infection.
Resumen de: US2025109186A1
Certain embodiments of the invention provide isolated anti-SARS-CoV-2 sdAbs, as well as polypeptides and protein molecules comprising such sdAbs. Certain embodiments of the invention also provide methods of using these sdAbs, polypeptides and protein molecules for treating or preventing a SARS-CoV-2 infection.
Resumen de: US2025109187A1
The present invention provides antibodies that bind to the SARS-CoV-2 Spike (S) protein. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using the aforementioned antibodies that bind to the SARS-CoV-2 Spike (S) protein.
Resumen de: US2025109421A1
The production process for a chimeric protein with SEQ ID No. 1, using the nucleotide sequence with SEQ ID No. 2; the chimeric protein defined by SEQ ID No. 1, the gene in SEQ ID No. 2 used for its production, immunogenic compositions containing the protein, and the use thereof to prepare vaccines for prophylaxis and prevention of infection and moderate and severe forms of COVID-19. The present technology falls within the field of human health, specifically in the field of preventive measures against infection with SARS-CoV2. It involves the production of a vaccine composition comprising a chimeric protein that prevents high viral loads and moderate and severe clinical forms of the disease by stimulating the immune system.
Resumen de: US2025109173A1
Provided is a recombinant polypeptide containing at least one immunogenic fragment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) spike glycoprotein, and pharmaceutical compositions containing the same.
Resumen de: US2025108107A1
Provided herein are SARS-CoV-2 spike proteins and polypeptides (e.g., SARS-CoV-2 spike proteins and polypeptide immunogens (and immunogenic fragments and immunogenic variants thereof)) comprising at least one set of amino acid substitutions, and nucleic acid molecules encoding the same. Further provided herein are compositions (e.g., pharmaceutical compositions) and vaccines comprising the same for use in e.g., the prevention, treatment, and/or amelioration of a SARS-CoV-2 infection.
Resumen de: WO2025072888A2
The present invention provides antibodies that bind to the SARS-CoV-2 Spike (S) protein. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using the aforementioned antibodies that bind to the SARS-CoV-2 Spike (S) protein.
Resumen de: AU2023334598A1
A method and an apparatus utilizing targeted ion mobility spectrometry for the detection of the SARS-CoV-2 virus and its variants, by measuring the quantity of free polyamines including putrescine, spermidine, and spermine in a sublingual saliva sample. Other embodiments are capable of providing instant, cost effective, POC testing and test results for other viral and bacterial infections including influenza, acute and chronic respiratory conditions, certain forms of inflammation, and the detection of certain abnormal cells in human subjects.
Resumen de: AU2023347083A1
This disclosure relates to RNA interference (RNAi) reagents for treatment of SARS-CoV-2 infection, compositions comprising same, and use thereof to treat or prevent infection by SARS- CoV-2.
Resumen de: AU2023336178A1
The invention relates to a polynucleotide encoding a) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein; and/or b) at least one non-structural SARS-CoV-2 protein selected from the group consisting of non-structural protein 7, non-structural protein 8, non-structural protein 9, non-structural protein 10, non-structural protein 11, non-structural protein 12, an endoribonuclease, and a 2'-O-methyltransferase, wherein the polynucleotide comprises or consists of at least one sequence part comprising codon-pair deoptimizations in comparison to the SARS-CoV-2 genome, and wherein the polynucleotide further comprises a furin cleavage site modification resulting in a loss of a furin cleavage site being naturally present in the SARS-CoV-2 genome. The invention further relates to a live attenuated SARS- CoV-2 comprising this polynucleotide, to a vaccine comprising this live attenuated SARS-CoV-2, as well as to associated methods.
Resumen de: US12266425B1
Provided are methods of assessing a biological sample obtained from an individual for the presence of a T cell that expresses a T cell receptor (TCR) comprising a TCRβ CDR3 sequence set forth in Table 1. Such methods further comprise identifying the individual as having COVID-19 when the presence of the TCR is detected. The presence of one or more of these TCRs may be of use in prognosticating severity of COVID-19 in the individual and the individual may be treated based on the expected severity of COVID-19. Treatment methods may include administering to the individual a T cell engineered to express the TCR. Such engineered T cells are also disclosed. Also provided are compositions and multimers that find use, e.g., in practicing the methods of the present disclosure.
Resumen de: AU2023329395A1
The present disclosure relates to compositions and methods for vaccinating a subject against multiple SARS-CoV-2 variants that involves the making and delivery of extracellular vesicles expressing on their surface engineered spike protein and/or engineered nucleocapsid protein to the subject. The present invention also relates to compositions and methods for the design, preparation, manufacture, formulation, and/or use of spike-display and nucleocapsid-display vesicular vaccines designed to elicit strong humoral and cellular immune responses against multiple SARS-CoV-2 variants.
Resumen de: KR20230153844A
The present invention relates to a biomarker for predicting or diagnosing COVID-19 severity, use thereof, a method for screening candidate substances for preventing, treating, or alleviating COVID-19, a biomarker for predicting or monitoring the progress of COVID-19, and use thereof. According to the present invention, the biomarker can accurately determine whether COVID-19 severity is present and can clearly determine the condition of a lesion and whether a patient improves after treatment. A biomarker composition for predicting or diagnosing COVID-19 severity comprises at least one selected from a group consisting of NEAT1, MALAT1, and combinations thereof, or a gene encoding the same.
Resumen de: US2024376178A1
The invention relates to antibodies useful for the prevention, treatment and/or diagnosis of coronavirus infections, and diseases and/or complications associated with coronavirus infections, including COVID-19. In particular, the invention relates to antibodies capable of binding to the spike protein of coronavirus SARS-CoV-2 and uses thereof.
Resumen de: KR20250042454A
본 발명의 일 실시예에 의하면, 해석가능한 인공지능을 이용한 우울 장애 예측 시스템이 제공될 수 있다. 우울 장애 예측 시스템은, 우울 장애 확률을 예측하기 위한 복수의 설명 변수 및 결과 변수에 대한 데이터를 포함하는 샘플 데이터를 수집하는 샘플 데이터 수집부; 분석 대상자의 우울 장애 확률을 예측하기 위한 복수의 학습 모델을 구축하고, 샘플 데이터를 이용하여 복수의 학습 모델에 대한 학습을 수행하는 학습 수행부; 구축된 복수의 학습 모델로부터 성능 통계에 기초하여 결과 변수에 영향을 미치는 설명 변수의 서브 세트를 구성하고, 각 서브 세트에 대한 복수의 학습 모델의 성능 통계에 기초하여 어느 하나의 설명 변수의 서브 세트를 선택하는 변수 선택부; 수집된 샘플 데이터의 선택된 설명 변수 및 결과 변수에 의해 복수의 학습 모델에 대한 학습을 수행하고, 각 학습 모델에 대한 성능 통계에 기초하여 분석 대상자의 우울 장애 확률을 예측하기 위한 하나의 학습 모델을 선택하는 학습 모델 선택부; SHAP(SHapley Additive exPlanations)을 이용하여 우울 장애 예측과 관련한 각 설명 변수의 영향도를 제공하는 영향도 산출부를 포함할 수 있다.
Resumen de: US2025099438A1
The invention relates to a class of small molecule inhibitors of GPR68/OGR1, a proton-sensing/stretch-sensing/sheer-stress-sending G-protein coupled receptor, and related receptors GPR4 and GPR65. These inhibitors are useful as a therapeutic for glioblastoma and other neoplasms, as a monotherapy or adjuvant, and also can be used as a treatment for other conditions, such as osteoporosis, inflammatory bowel disease, autoimmune and chronic inflammatory diseases such as multiple sclerosis and inflammatory pain syndromes, GERD, aspiration pneumonitis, bacterial and viral pneumonia, COPD, acute respiratory distress syndrome (ARDS), and COVID-19.
Resumen de: US2025099573A1
Provided are a polypeptide antigen derived from the S protein of SARS-CoV-2, a polypeptide vaccine containing the same, and applications thereof. The amino acid sequence of the polypeptide antigen provided by the present disclosure is as shown in any one of SEQ ID NOs: 1-116.
Nº publicación: US2025099444A1 27/03/2025
Solicitante:
INCELLDX INC
IncellDx, Inc
Resumen de: US2025099444A1
Methods of treating a subject for long-haul COVID are provided. Aspects of the methods include administering to the subject a tropane CCR5/CCL5 interaction inhibitor in combination with a statin to treat the subject for long-haul COVID. Also provided are compositions for use in practicing the methods.
BOPI
Sede Electrónica
